Clinical trial for prevention of anti-EGFR antibody induced acneiform eruption

An Asessor-blind, within-participant randomized controlled trial to evaluate the efficacy and safety of vitamin C derivative in anti-EGFR antibody-induced acneiform eruption

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041240009

Enrollment

Registered

2024-04-08

Start date

2024-07-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Application of vitamin C derivative

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Has provided written consent for participation - Age 18 or greater at the time of consent - With ECOG PS 0-2 - Diagnosed with colorectal cancer - Scheduled to receive chemotherapy including anti-EGFR antibody drugs

Exclusion criteria

Exclusion criteria: - Has received anti-EGFR antibody drugs in the past - With a history of acneiform eruptions - With a history of hypersensitivity to tetracyclines - With skin lesions or scarring at the site of evaluation - Pregnant or possibly pregnant women - Lactating women - Deemed ineligible for the study as determined by the principal investigator or a co-investigator

Design outcomes

Primary

Measure	Time frame
Difference in the number of skin rashes between vitamin C derivative-applied and non-applied surfaces	—

Secondary

Measure	Time frame
Skin rashe area, Grading	—

Contacts

Public ContactKoseki Takenao

Fujita Health University

tkoseki@fujita-hu.ac.jp+81-562-93-9396

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026